| INTRODUCTION
Prostate cancer (PCa), a form of adenocarcinoma developed in prostate epithelium, is the most commonly diagnosed male malignancy and the second leading-cause of cancer-related death in men. 1 Androgen receptor (AR), a member of the nuclear receptor (NR) superfamily, is an androgen-dependent transcriptional factor that regulates gene expression required for the survival and proliferation of prostate epithelial cells, thereby promoting prostatic development and, ironically, driving prostatic tumorigenesis, and PCa progression. 2, 3 AR is a modular protein with several defined structural domains with distinct functions. The long and intrinsically unstructured N-terminal domain (NTD) is required for transcription activation, 4 probably through recruiting coregulators such as CBP (CREBBP) and p300 (EP300). 5, 6 The short DNA-binding domain (DBD) folds into a defined structure that recognizes specific DNA sequences known as androgenresponsive elements (AREs). 7 The structured C-terminal domain, linked to the DBD by an unstructured hinge region, contains the ligand-binding pocket that specifically binds androgens, thus termed ligand-binding domain (LBD). 2, 8 Because androgens are critical for AR nuclear translocation and transactivation of AR target genes, androgen deprivation (ADT), and antiandrogen therapies through either surgical or medical castration have been widely used as PCa therapies. 9 These therapies work well initially, but in recurring PCa, the cancer cells become more aggressive and castration-resistant. Once metastatic diseases develop from castration-resistant PCa (CRPC), which occurs near the end stages of the disease, the hope of patient survival diminishes dramatically with a median survival of only about 18 months. Surprisingly, the transcriptional activity of AR remains crucial for the survival and proliferation of PCa cells even after they become castrationresistant. 10 Indeed, in model prostate xenografts when the tumor becomes castration resistant, gene expression analysis revealed that AR signaling pathways are consistently upregulated. 11 In addition, targeting CYP17, an enzyme key to androgen and estrogen biosynthesis, with the specific inhibitor abiraterone acetate (Zytiga), improves CRPC patient survival, indicating continued dependence of CRPC on AR signaling pathways. 12 Beneficial clinical responses were also observed with the second-generation AR antagonist MDV3100
(enzalutamide) for CRPC. 13 A decline of prostate-specific antigen (PSA) was used as the primary surrogate indicator of antitumor activity in early clinical trials using both Zytiga and MDV3100. 10 PSA expression is driven predominantly by the upstream ARE-containing enhancer.
PSA levels eventually increase and are associated with disease progression for the majority of patients receiving treatment with Zytiga and MDV3100, suggesting that AR reactivation may underpin the therapeutic resistance. 10 Acquired AR LBD mutations and increased intratumoral androgen biosynthesis have been shown to contribute to therapeutic resistance to MDV3100 14 and Zytiga, 15 respectively. The elevated expression of C-terminally truncated AR variants (AR-Vs) has been observed in CRPC and correlates with poor patient prognosis. [16] [17] [18] [19] [20] AR-Vs contain an NTD and DBD but not an LBD, and thus are capable of directing AR target gene expression. 21 Indeed, AR-Vs are ligand-independent and constitutively active transcriptional activators. 22, 23 These independent mechanisms of AR reactivation highlight the challenges of using current hormone therapies to achieve durable inhibition of AR signaling. Thus, alternative strategies to suppress AR reactivation are needed to attain durable AR inhibition for effectively treating CRPC.
The early region 1A (E1A) of the adenovirus genome expresses several alternatively spliced mRNAs encoding various E1A isoforms. 24 The two widely studied Ad5 E1A splice variants encode for the 289-residue (herein referred to as E1A5) and the 243-residue (e1a5)
proteins. These E1A proteins contain several conserved regions (CR1-4). E1A is intrinsically unstructured with the exception for a zincfinger structure encoded by CR3 that is deleted in the e1a5 isoform. 25 LI ET AL.
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E1A5 is a powerful transcriptional activator owing to its strong interactions with the transcriptional machinery and coregulators such as p300/CBP. 26 E1A does not directly bind to DNA, but CR3 along with adjacent sequences have been shown to interact with diverse DNAbinding transcription factors (TFs). 27, 28 The 243-residue e1a5 does not bind to TFs, 27, 28 although it can modulate transcription, for example, by sequestering coregulators. Indeed, e1a5 seems to inhibit ARmediated transcription, presumably through sequestering coactivators p300/CBP. 5, 29 Interestingly, the N-terminal domain of E1As contains a conserved sequence motif that resembles the hydrophobic NRinteracting sequence found in corepressors (CoRs) such as NCORs.
Through this motif, E1As can compete against CoRs for binding to NRs, thereby promoting NR activation. 30, 31 There are >50 serotypes of human adenoviruses. The expression plasmids for wild-type (wt) E1A12 and various mutants were reported previously. 38 The full-length AR (GFP-AR, plasmid # 28235) and AR-V7 (GFP-AR-V7, plasmid # 86856) fused to GFP were obtained from Addgene, Cambridge, MA. The mCherry-AR construct was made by inserting the full-length AR cDNA fragment from the GFP-AR plasmid at the 3′ end of the mCherry coding sequence. FLAGtagged AR NTD (1-566) and AR NTD-DBD-Hinge (1-802) were generated by PCR using the GFP-AR as template and cloned into pExchange-3B. FLAG-tagged full-length AR and constructs with a specific deletion within the AR NTD were described. 39 Ad-E1A12 and other viruses with mutated E1A12 were constructed as reported previously. 38 Recombinant viruses were generated through homologous recombination between pShuttle-CMV carrying the E1A12 expression cassette and pAdEasy-1, an E1, and E3-deleted Ad vector (Agilent Technologies, Santa Clara, CA). 40 Ad-E1A12 was packaged in HEK293 cells. The recombinant viruses expressing a mutated E1A12
were constructed similarly. A large-scale preparation of purified Ad-E1A12 viral particles was done by ViraQuest, Inc., North Liberty, IA, Ad-eGFP and wt Ad5 were purchased from ViraQuest, Inc.
| Luciferase reporter gene assay
The AR NTD (aa 1-566) was fused to the C-terminus of Gal4 DNAbinding domain (Gal4-BD). The firefly luciferase reporter is under the control of an artificial promoter containing five copies of Gal4-binding sites upstream of the Ad5 E4 core promoter consisting of a TATA box and an initiator element. 41 This reporter and the sea pansy (Renilla) luciferase reporter were co-transfected into Saos-2 or DU145 cells along with indicated combinations of expression plasmids in triplicate.
At 24 h after transfection, cells were washed twice with phosphatebuffered saline (PBS) and then lysed for the dual luciferase assay according to manufacturer's protocol (Promega, Madison, WI). The firefly luminescence readouts were normalized against the Renilla luciferase readouts in each transfection. For mammalian two-hybrid assays, the AR LBD (aa 690-919) was fused to Gal4-BD and the AR NTD (aa 1-566) was fused to the C-terminus of VP16 activation domain.
Transfections and luciferase assays were performed similarly as above.
| Cell viability assay
Cells were seeded in triplicate in a 96-well plate. At 24 h after seeding, viruses were added to cell cultures. At 2 h after viral infection, vehicle (DMSO) or a specific inhibitor was added to the cell cultures. At 96 h after adding adenoviruses, cell viability assays were performed using CellTiter-Glo reagent (Promega) essentially as reported previously. 42 The luminescence readouts were subsequently averaged and normalized against a relevant control.
| Quantitative real-time RT-PCR
LNCaP or R1-AD1 cells were uninfected or infected with Ad-eGFP, or Ad-E1A12 (1000 viral particles (vps)/cell). At 48 h post-infection, RNAs were extracted using the RNeasy kit (Qiagen, Germantown, MD). cDNAs were synthesized from total RNAs using MultiScribe reverse transcriptase kit (Applied Biosystems, Foster City, CA), which were used as templates for real-time PCR with the SYBR-green detection method. Quantification was as described previously. 38 The PCR primers were: AR (5′-CAGTG-GATGGGCTGAAAAAT-3′ and 5′-GGAGCTTGGTGAGCTGGTAG-3′); 
| Western blotting
Cells were seeded and cultured in multi-well plates. At 24 h after seeding, adenovirus alone or together with a specific inhibitor was added (drug was After washes, the membrane was incubated with a proper secondary antibody at room temperature for 45 min. Proteins were detected using the Immobilon Western blot Chemiluminescent kit (Millipore).
| Immunoprecipitation (IP)
LNCaP or R1-AD1 cells were infected with Ad-E1A12 at the multiplicity of infection (MOI) of 100 vps/cell. The infected cells were collected at and were subjected to an antibody staining protocol as described. 3 | RESULTS
| E1A12 inhibits AR NTD-mediated transactivation
Previous studies indicated that the 243-residue isoform of Ad5 E1A
(e1a5) interferes with AR activation, possibly through sequestration of transcriptional coactivators p300/CBP. 5 To assess potential effects of the large E1A isoforms of various Ad species (serotypes), we conducted luciferase reporter gene assays using AR NTD fused to Gal4-BD. AR NTD increased the luciferase activity by ∼20-fold, similar were assessed using Western blotting. The E1A12 and E1A5 expression levels were similar (note that the polyclonal anti-E1A12
antibody recognizes both E1A12 and E1A5), although AR NTD levels were slightly reduced when either E1A5 or E1A12 were coexpressed ( Figure 1A ). Because E1A12 and E1A5 displayed opposite effects on AR NTD-mediated transcription, the functional impact of E1As on AR must not be due to the moderate reduction of AR NTD expression.
Indeed, similar effects on AR-mediated transactivation by E1A12
(repression) and E1A5 (activation) were seen, even though the levels of AR NTD proteins were largely unchanged (Figure 1B lanes 9 and 10).
We also examined the effects of E1As from other Ad species on AR NTD-mediated transactivation. We found that E1As from Ad3, Ad4, Ad9, and Ad40 all suppressed AR NTD-mediated transcription ( Figure 1B) . Surprisingly, the levels of AR NTD fusion construct with Gal4-BD were markedly reduced when coexpressed with these E1A constructs (compare lanes 11-14 to lane 2, in the lower panel of Figure 1B ). Thus, it is possible that these E1A constructs might trigger degradation of AR NTD, which could also contribute to the inhibition of AR NTD-mediated transactivation. Figure 3B ).
Both the 266 aa and 235 aa isoforms of E1A12 were exclusively or predominantly nuclear in the absence (panels 3-6, Figure 3A) or presence of the androgen analog R1881 (panels 17-20 in Figure 3A) . infection, as the DBP expression strictly requires E1A12 expression. 38 Thus, E1A12 266 aa was able to promote the nuclear entry of endogenous AR, although the potency to stimulate AR nuclear translocation by E1A12
266 aa was notably weaker than R1881 ( Figure 4B ).
To further examine AR-E1A12 interactions, E1A12 and GFP-AR
were expressed alone or together in the AR-negative PC-3 ( Figure 4C Figures 4C and 4D ). By contrast, in cells co-expressing both E1A12 and GFP-AR, although predominantly localized to the nucleus, notable presence of both AR and E1A12 in the cytoplasm became apparent (panels e-g, Figures 4C and 4D ), suggesting that E1A12 interacts with AR in both the cytoplasm and the nucleus.
Furthermore, we tested whether AR could induce redistribution of E1A12 from its binding partners. To this end, we co-expressed CBX4
(also known as PC-2), a component of the Polycomb group (PcG) PRC1 complex that we found to colocalize with E1A12 in PcG nuclear bodies (panels h-j in Figures 4C and 4D ). CBX4 did not obviously colocalize with GFP-AR (panels k-m, Figures 4C and 4D) . However, when E1A12, GFP-AR, and RFP-CBX4 were co-expressed, E1A12 was radically redistributed from PcG bodies to the nucleoplasm, similar to the intracellular distribution of GFP-AR (panels n-p, Figures 4C and 4D ), suggesting that AR expression forces E1A12 to dissociate from PcG bodies due to stronger AR-E1A12 interactions. Together, these data suggest that E1A12-AR interaction is quite strong, probably dominant over E1A12's associations with other interacting proteins.
| E1A12 266aa bridges an interaction between AR NTD and LBD
Androgens have been shown to promote biologically relevant inter-or intramolecular interactions between the AR N-and C-terminal domains. 45, 46 The AR N-terminal FXXLF motif is thought to interact with a hydrophobic binding pocket in LBD upon ligand binding. The AR N/C interaction has been suggested to promote AR nuclear translocation, to slow the dissociation of agonist, and to stabilize AR. 46, 47 We showed that E1A12 266 aa could promote the AR nuclear translocation in the absence of androgen (Figures 3 and 4) , which could be attributed to the ability of E1A12 266 aa to mediate an AR N/C interaction. To test this hypothesis, we conducted mammalian twohybrid assays using Gal4-BD-LBD (aa 690-919) and NTD (aa 1-566)-VP16 hybrid constructs in transfected cells. Data presented in Figure 5 indicate that the expression of E1A12 or the E1A12-ΔN mutant capable of high-affinity ligand-binding. 46 These results demonstrate that E1A12 can bridge a unique AR N/C interaction ( Figure 5B ).
| E1A12 266 aa inhibits the expression of AR target genes
To assess functional impact of E1A12 266 aa on AR-mediated gene expression, LNCaP and R1-AD1 cells were mock treated or infected with Ad-eGFP or Ad-E1A12. As shown in Figure 6 , Ad-E1A12 infection resulted in reduced expression of AR and classical AR target genes FKBP5 and ATAD2. MYC expression is regulated by AR. 48 Ad-E1A12 also downregulated MYC as well as MYC target genes GLUD1 encoding glutamate dehydrogenase 1, 49 and TFRC encoding transferrin receptor protein 1, 50 which has been explored as a tractable biomarker for monitoring MYC inhibition in a PCa therapeutic setting. 51 These results indicate that E1A12 266 aa can repress the expression of certain AR target genes.
| AR-expressing PCa cells display heightened sensitivity to Ad-E1A12-mediated killing
Inhibition of AR by E1A12 may compromise the survival for PCa cells, in particular those depending on AR for growth. To test this, we infected PCa cell lines with Ad-E1A12. The viability of Ad-E1A12 The cross-inhibitory effects between PI3K-AKT pathway and AR signaling pathway have been observed. Inhibition of one pathway resulted in enhanced signaling of the other. 52, 53 Ad infection can activate the PI3K-AKT-mTOR pathway 54 ; we reported recently that Ad-E1A12 infection markedly activates this pathway. 38 We thus and R1-I567 ( Figure 7C ). However, both R1-D567 and R1-I567 were also sensitive to Ad-E1A12-mediated killing, although R1-I567 was notably more resistant to Ad-E1A12 infection ( Figure 7C ). In contrast, all three lines displayed similar survival profiles upon infection with the control Ad-eGFP virus ( Figure 7C ). Similar to LNCaP cells, both BEZ235 and temsirolimus, albeit moderately, enhanced Ad-E1A12-induced apoptosis in both R1-AD1 ( Figure 7D ) and R1-I567 ( Figure 7E) cell lines. Taken together, these observations support the idea that targeting AR by E1A12 represents a major mechanism for killing PCa cells, and that pharmacological inhibition of mTOR signaling augments the potency of Ad-E1A12 to kill AR-expressing PCa cells.
| Molecular events in Ad-E1A12-infected cells
We assessed potential molecular mechanisms that may contribute to the synergistic killing of cancer cells by Ad-E1A12 and mTOR inhibition. Figure 8A ). Interestingly, AR protein levels were markedly reduced in wt Ad5-infected cells in the presence of BEZ235 (lanes 14).
To assess whether AR downregulation was due to proteasomemediated degradation, the proteasome inhibitor MG132 was added to the infected cells. However, MG132 did not restore AR expression (lane 28 of Figure 8A ). The expression of PSA was not obviously altered by viral infection or BEZ235 treatment (lanes 1-7 in the PSA panel in Figure 8A ). However, exposure of LNCaP cells to both BEZ235 and MG132 reduced PSA expression, especially in cells also infected with viruses ( Figure 8A lanes 24-28 of the PSA panel) . The inability of Ad-E1A12 to suppress PSA expression is possibly due to the activation of AKT in virus-infected PCa cells, 38 as AKT activation drives ARmediated PSA expression. Consistent with data shown in Figure 8A , AR protein levels were not impacted by E1A12 irrespective of androgen stimulation ( Figure 8B ).
Genes involved in lipid metabolism have been shown to be regulated by AR in PCa cells. 61 Indeed, the fatty acid synthase (FAS) and acetyl-CoA carboxylase 1 (ACC1) were markedly upregulated upon androgen stimulation ( Figure 8B ). However, Ad-E1A12 infection did not affect the expression of FAS or ACC1. Interestingly, R1881 also stimulated the expression of acetyl-coenzyme A synthetase (ACSS2), and Ad-E1A12 infection reduced ACSS2 levels in LNCaP cells exposed to R1881
(compare lanes 6 with 4 and 12 with 10 in Figure 8B ), suggesting E1A12
interferes with androgen-stimulated ACSS2 expression.
Interestingly, the expression of the adenoviral DBP was markedly increased upon R1881 stimulation in LNCaP cells infected with Ad-E1A12. DBP is required for Ad replication. 62 As shown previously, However, androgens were not required for E1A12 to mediate an AR N/C interaction, as this N/C interaction was also detected in mammalian twohybrid assays in the absence of androgens (data not shown). Furthermore, E1A12 promotes AR nuclear translocation in the absence of androgens (Figures 3 and 4) . Nonetheless, there is no experimental evidence yet as to FIGURE 8 Functional impact of Ad-E1A12 on AR and cell death. A, LNCaP cells were uninfected (mock) or infected with an indicated virus (100 viral particles/cell). At 2 h after adding virus, the cells were either exposed to the solvent (DMSO) or BEZ235 (0.1 μM). In a separate set of cell cultures, the proteasome inhibitor MG132 was also added 6 h before cell lysis to the final concentration of 27 μM. At 24 h post infection, cells were harvested for Western blotting analysis with antibodies against the indicated proteins. E-Cadherin, PCNA and Hsp60 were detected as loading controls. B, LNCaP cells were cultured in DMEM medium with 10% regular serum (fetal bovine serum, FBS) or 10% CSS as indicated. Cells were treated with ethanol, or R1881 (10 nM), and then infected with Ad-eGFP or Ad-E1A12. Cell lysates were subject to SDS-PAGE and Western blotting as in A whether E1A12 indeed binds to AF-2. Alternatively, E1A12 could also contact other sites in LBD, which might enable the FQNLF motif in the AR The ability of E1A12 to bind specifically to the AR and inhibit its transactivation function suggests that Ad-E1A12 might have an unprecedented therapeutic potency for treating advanced PCa.
Notably, we observed that Ad-E1A12 infection hyperactivated the PI3K-AKT-mTOR pathway ( Figure 8A ). 38 This can be attributed to Adintrinsic factors that trigger the independent activation of both PI3K-AKT and mTOR pathways upon Ad infection. 54 Additionally, AR inhibition by E1A12 could further activate the PI3K-AKT signaling, as cross-inhibitory effects between the PI3K-AKT and AR signaling pathways have been observed 52, 53 ; thus, inhibition of one pathway resulted in enhanced signaling of the other. Activation of the PI3K-AKT signaling pathway is a hallmark of CRPC. Loss of PTEN or activation of PI3K occurs in up to 70% of late stage PCa cases, 65 leading to PCa cell proliferation, survival, and invasion and androgen-independent growth phenotype. Therefore, cotargeting both pathways is expected to enhance therapeutic efficacy against CRPC. 52, 53 We demonstrated that Ad-E1A12 infection in combination with pharmacological inhibition of the PI3K-AKT-mTOR pathway is synthetically lethal to LNCaP cells (Figure 7) . Thus, Ad-E1A12 in conjunction with inhibitors of the PI3K-AKT-mTOR pathway such as various mTOR kinase inhibitors might be a particular powerful modality for treating CRPC. Alternatively, the deletion of E4 ORFs in Ad-E1A12 vector could remove the viral factors that hyperactivate AKT and mTOR, thereby bypassing the cell surviving mechanisms. Such a vector is expected to be lethal in killing PCa cells without AKT/mTOR inhibitors.
Active suppression of the host DNA damage response (DDR) is important for efficient production of the linear double-stranded Ad genome. 66 The histone-like Ad core protein VII associates with host chromatins and inhibits ATM-mediated phosphorylation of H2AX, resulting in reduced levels of γ-H2AX. 66 Interestingly, Ad-E1A12
infection increased the level of γ-H2AX ( Figure 8A lane 3) , which was further elevated by proteasomal inhibition ( Figure 8A lane 17) , probably due to reduced proteasomal degradation of H2AX mediated by the E3 ubiquitin ligase HUWE1. 67 It has been shown that γ-H2AX is critical for apoptotic cell death. [58] [59] [60] Thus, it appears likely that γ-H2AX
accumulation may be an important event leading to apoptosis in Ad-E1A12-infected cells as evidenced by the appearance of cleaved PARP-1 ( Figure 8A ). Of note, p53 expression appears to depend on AKT signaling in LNCaP cells ( Figure 8A ). Nonetheless, p53 levels did not strictly correlate with the appearance of cleaved PARP-1 ( Figure 8A ). 
